Phase 2 Trial of the Combination of the BET inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Locations

University of Colorado Hospital

Principal Investigator
Photograph of Bradley Corr

Bradley Corr

Study ID

Protocol Number: 23-0145

More information available at ClinicalTrials.gov: NCT05327010

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers